Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03068949 · ClinicalTrials.gov registry record · Phase 4
Comparison of Three Licensed Influenza Vaccines
A Phase 4 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 4
- Development phase
- 413
- Enrollment target
NCT03068949 is a Phase 4 study that has completed, run by University of Rochester. The registered enrollment target is 413 participants.
The verdict
NCT03068949, a Phase 4 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 413 participants
- Enrollment target
Study Summary
This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.
Interventions
- BIOLOGICAL Fluzone
- BIOLOGICAL FluBlok
- BIOLOGICAL FluCelVax
- BIOLOGICAL Fluzone HD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03068949
The ClinicalTrials.gov registry entry for NCT03068949 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluzone is the first listed.
NCT03068949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03068949 about?
NCT03068949 is a clinical study titled "Comparison of Three Licensed Influenza Vaccines". This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.
What is the current status of trial NCT03068949?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 413 participants. The study started on 2015-10-28. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03068949?
The interventions under investigation include: Fluzone (BIOLOGICAL), FluBlok (BIOLOGICAL), FluCelVax (BIOLOGICAL), Fluzone HD (BIOLOGICAL).
Who is sponsoring clinical trial NCT03068949?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.